Phase II Study of Oxaliplatin in Patients With Unresectable, Metastatic, or Recurrent Hepatocellular Cancer-Reference-Cited by-同舟云学术

Phase II Study of Oxaliplatin in Patients With Unresectable, Metastatic, or Recurrent Hepatocellular Cancer

Published:2008-08 Issue:4 Volume:31 Page:317-322
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Yen Y,Lim Dean W.,Chung Vincent,Morgan Robert J.,Leong Lucille A.,Shibata Stephen I.,Wagman Stephen D.,Marx Howard,Chu Peiguo G.,Longmate Jeffrey A.,Lenz Heinz-Josef,Ramanathan Ramesh K.,Belani Chandra P.,Gandara David R.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference25 articles.

1. Cancer statistics, 2005.;Jemal;CA Cancer J Clin,2005

2. Systemic treatment and liver transplantation or hepatocellular carcinoma: two sides of the therapeutic spectrum.;Burroughs;Lancet Oncol

3. Hepatocellular carcinoma.;Di Bisceglie;Ann Intern Med,1998

4. Treatment of hepatocellular carcinoma: too many options?;Venook;J Clin Oncol,1994

5. Clinical trials in primary hepatocellular carcinoma: current status and future directions.;Nerenstone;Cancer Treat Rev,1988

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review;Expert Review of Anticancer Therapy;2024-04-24

2. Research Progress of UBE2S in Digestive Sys-tem Tumors;Advances in Clinical Medicine;2023

3. SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback;Cancer Letters;2022-03

4. Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook;Journal of Hepatocellular Carcinoma;2022-03

5. UBE2S promotes cell chemoresistance through PTEN-AKT signaling in hepatocellular carcinoma;Cell Death Discovery;2021-11-16